The Immune Thrombocytopaenia Treatment Landscape: A Focus on Patient Perspectives and Unmet Clinical Needs

This content was funded by Sanofi.

In this video, learn about what is new and important in the treatment of immune thrombocytopaenia, with a focus on patient perspectives and unmet clinical needs.

Chapters:

• 00:00–02:20 – Introduction (David J. Kuter, USA [Chair])
• 02:45–21:50 – What are the Key Clinical Concerns When Choosing Treatment? (Waleed Ghanima, Norway)
• 22:15–37:00 – How to Navigate Patient Concerns with Clinical Outcomes (Cindy Neunert, USA)
• 37:05–59:00 – Can Emerging Treatments Help Fill the Gaps? (David J. Kuter, USA)
• 59:05–1:13:05 – Closing and Q&A (All faculty – moderated by Chair)

1. Head of Research and Consultant Haematologist, Østfold Hospital; and Professor at the Institute of Clinical Medicine, University of Oslo, Norway. Ghanima is a Principal Investigator in the Phase 3 rilzabrutinib study, LUNA 3.
2. Program Director of Hematology, Massachusetts General Hospital; and Professor of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
3. Associate Professor of Pediatrics, Columbia University Irving Medical Center, New York, USA. Neunert received fellowship training in Pediatric Hematology-Oncology at the University of Texas Southwestern Medical School, Dallas, Texas, USA, where she also obtained her master’s degree in clinical research.